Dimensional Fund Advisors LP lifted its position in Prothena Co. PLC (NASDAQ:PRTA) by 34.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,272,832 shares of the biotechnology company’s stock after buying an additional 328,166 shares during the period. Dimensional Fund Advisors LP owned approximately 3.19% of Prothena worth $13,110,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Prothena by 1.3% in the 4th quarter. BlackRock Inc. now owns 3,354,654 shares of the biotechnology company’s stock valued at $34,553,000 after purchasing an additional 43,266 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Prothena by 82.9% in the 4th quarter. Bank of New York Mellon Corp now owns 373,072 shares of the biotechnology company’s stock valued at $3,842,000 after purchasing an additional 169,070 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of Prothena in the 3rd quarter valued at $2,714,000. Thrivent Financial for Lutherans lifted its stake in shares of Prothena by 7.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 104,394 shares of the biotechnology company’s stock valued at $1,365,000 after purchasing an additional 6,998 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Prothena by 1,145.1% during the third quarter. JPMorgan Chase & Co. now owns 101,599 shares of the biotechnology company’s stock worth $1,329,000 after acquiring an additional 93,439 shares during the period.
Shares of PRTA traded down $0.12 during mid-day trading on Friday, reaching $10.36. The stock had a trading volume of 247,347 shares, compared to its average volume of 249,125. The company has a current ratio of 27.85, a quick ratio of 28.90 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $417.78 million, a P/E ratio of -2.87 and a beta of 2.40. Prothena Co. PLC has a 52-week low of $8.63 and a 52-week high of $17.60.
A number of research firms have weighed in on PRTA. BidaskClub cut shares of Prothena from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. ValuEngine upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research report on Tuesday, April 23rd. Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, February 13th. Finally, Cantor Fitzgerald assumed coverage on shares of Prothena in a research report on Monday, March 4th. They issued an “overweight” rating and a $13.77 target price for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $13.26.
ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Increases Stake in Prothena Co. PLC (PRTA)” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/11/dimensional-fund-advisors-lp-acquires-328166-shares-of-prothena-co-plc-prta.html.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Further Reading: Straddles
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.